← Back to Screener
ADMA Biologics, Inc. (ADMA)
Price$10.74
Favorite Metrics
Price vs S&P 500 (26W)-31.14%
Price vs S&P 500 (4W)-34.20%
Market Capitalization$2.58B
P/E Ratio (Annual)17.55x
All Metrics
P/CF (Annual)51.18x
Book Value / Share (Quarterly)$2.01
P/TBV (Annual)9.11x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)49.04%
Cash Flow / Share (Quarterly)$0.12
Price vs S&P 500 (YTD)-44.25%
Gross Margin (TTM)57.39%
Net Profit Margin (TTM)28.80%
EPS (TTM)$0.60
10-Day Avg Trading Volume5.10M
EPS Excl Extra (TTM)$0.60
Revenue Growth (5Y)64.62%
EPS (Annual)$0.60
ROI (Annual)26.74%
Gross Margin (Annual)57.39%
Net Profit Margin (5Y Avg)-13.41%
Cash / Share (Quarterly)$0.37
P/E Basic Excl Extra (TTM)17.55x
Revenue Growth QoQ (YoY)18.39%
P/E Normalized (Annual)17.55x
ROA (Last FY)23.54%
Revenue Growth TTM (YoY)19.63%
EBITD / Share (TTM)$0.77
ROE (5Y Avg)-5.51%
Operating Margin (TTM)36.87%
Cash Flow / Share (Annual)$0.12
P/B Ratio5.40x
P/B Ratio (Quarterly)9.09x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.03x
Net Interest Coverage (TTM)35.86x
ROA (TTM)25.98%
EPS Growth QoQ (YoY)-54.98%
EV / EBITDA (TTM)13.63x
EPS Incl Extra (Annual)$0.60
Current Ratio (Annual)6.71x
Quick Ratio (Quarterly)3.63x
3-Month Avg Trading Volume4.31M
52-Week Price Return-49.07%
EV / Free Cash Flow (Annual)93.21x
P/E Incl Extra (TTM)17.55x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$2.00
P/S Ratio (Annual)5.06x
Asset Turnover (Annual)0.82x
52-Week High$25.67
Operating Margin (5Y Avg)-6.93%
EPS Excl Extra (Annual)$0.60
CapEx CAGR (5Y)12.45%
Tangible BV CAGR (5Y)40.88%
26-Week Price Return-27.15%
Quick Ratio (Annual)3.63x
13-Week Price Return-40.60%
Total Debt / Equity (Annual)0.15x
Current Ratio (Quarterly)6.71x
Enterprise Value$2,563.777
Revenue / Share Growth (5Y)33.56%
Asset Turnover (TTM)0.90x
Book Value / Share Growth (5Y)18.97%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.15x
Pretax Margin (Annual)35.80%
Cash / Share (Annual)$0.37
3-Month Return Std Dev73.05%
Gross Margin (5Y Avg)33.70%
Net Income / Employee (TTM)$0
ROE (Last FY)30.78%
Net Interest Coverage (Annual)35.86x
EPS Basic Excl Extra (Annual)$0.60
P/FCF (TTM)48.69x
Receivables Turnover (TTM)4.90x
EV / Free Cash Flow (TTM)93.21x
Total Debt / Equity (Quarterly)0.15x
EPS Incl Extra (TTM)$0.60
Receivables Turnover (Annual)4.90x
ROI (TTM)29.82%
P/S Ratio (TTM)5.06x
Pretax Margin (5Y Avg)-15.38%
Revenue / Share (Annual)$2.08
Tangible BV / Share (Annual)$2.00
Forward P/E11.71x
Price vs S&P 500 (52W)-78.90%
P/E Ratio (TTM)17.55x
EPS Growth TTM (YoY)-25.56%
Year-to-Date Return-41.61%
5-Day Price Return7.14%
EPS Normalized (Annual)$0.60
ROA (5Y Avg)2.12%
Net Profit Margin (Annual)28.80%
Month-to-Date Return18.20%
Cash Flow / Share (TTM)$-0.07
EBITD / Share (Annual)$0.77
Operating Margin (Annual)36.87%
LT Debt / Equity (Annual)0.15x
P/CF (TTM)51.18x
ROI (5Y Avg)2.07%
P/E Excl Extra (TTM)17.55x
LT Debt / Equity (Quarterly)0.15x
EPS Basic Excl Extra (TTM)$0.60
P/TBV (Quarterly)9.11x
P/B Ratio (Annual)9.09x
Inventory Turnover (TTM)1.15x
Pretax Margin (TTM)35.80%
Book Value / Share (Annual)$2.01
Price vs S&P 500 (13W)-41.29%
Beta0.88x
P/FCF (Annual)93.77x
Revenue / Share (TTM)$2.10
ROE (TTM)34.98%
52-Week Low$7.21
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ADMAADMA Biologics, Inc. | 5.06x | 19.63% | 57.39% | — | $10.74 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
ADMA Biologics manufactures and markets plasma-derived immunoglobulin (IG) and intravenous immunoglobulin (IVIG) products for immunodeficient patients and those at risk for infectious diseases. The company operates through ADMA BioManufacturing, its primary revenue source, and Plasma Collection Centers, supplemented by laboratory and contract manufacturing services. It also sells plasma-derived intermediate fractions generated from its FDA-approved manufacturing process. The company derives substantially all revenue from the United States market.